Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
1(11%)
Results Posted
14%(1 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_2
4
44%
Ph phase_3
2
22%
Ph phase_1
3
33%

Phase Distribution

3

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(7)
Terminated(1)

Detailed Status

Completed7
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
87.5%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (33.3%)
Phase 24 (44.4%)
Phase 32 (22.2%)

Trials by Status

terminated111%
completed778%
recruiting111%

Recent Activity

1 active trials
Showing 5 of 9
recruitingphase_1

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

NCT06134375
terminatedphase_2

Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer

NCT00195091
completedphase_1

Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer

NCT01837329
completedphase_3

Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis

NCT00805805
completedphase_2

Tetrathiomolybdate in Hormone Refractory Prostate Cancer

NCT00150995
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06134375Phase 1

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Recruiting
NCT00195091Phase 2

Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer

Terminated
NCT01837329Phase 1

Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer

Completed
NCT00805805Phase 3

Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis

Completed
NCT00150995Phase 2

Tetrathiomolybdate in Hormone Refractory Prostate Cancer

Completed
NCT00189176Phase 1

Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis

Completed
NCT00176774Phase 2

Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma

Completed
NCT00004339Phase 3

Study of Tetrathiomolybdate in Patients With Wilson Disease

Completed
NCT00006332Phase 2

Treatment of Hepatocellular Carcinoma With Tetrathiomolybdate

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9